Ms. Doyle brings an entrepreneurial mindset with a deep understanding of large pharma that spans more than 20 years of experience. Ms. Doyle joined Halozyme in May of 2021 as the Senior Vice President and General Manager of ENHANZE®. She is responsible for overseeing Halozyme’s ENHANZE® drug delivery technology, including responsibility for the annual operating plan and long-term growth strategy for the franchise. Ms. Doyle will oversee the alliance management, ENHANZE® business development, regulatory and safety, and project management functions within Halozyme.
Prior to Halozyme, Ms. Doyle served as Senior Vice President of all Regions and Commercial for Biocon where she oversaw Biocon Biologics’ biosimilars business and reported to the Chief Executive Officer of Biocon Biologics. Throughout her 15-year career at Novartis Ms. Doyle held many leadership roles most recently as a VP, Global head Healthcare systems in the US and prior to that Country leadership roles as GM in Canada as well as in countries in Eastern and Western Europe. Ms. Doyle started her career in Novartis heading up the Neuroscience franchise before migrating to Oncology. Prior to Novartis Ms. Doyle held positions at Abbott, and other pharma companies and in MIT.
Ms. Doyle received a B.S. in Biochemistry from Trinity College in Dublin (Dublin University) and a degree in International Business and Marketing Ireland and did post graduate research at MIT/Harvard.